Stocktoria
HARROW, INC. HROW
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-02-08
HARROW, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 75.1% | 75.3% | 69.6% | 71.3% | 74.9% |
| Operating margin | 11.2% | 4.4% | 0.3% | 2.2% | 2.2% |
| Net margin | -1.9% | -8.8% | -18.7% | -15.9% | -24.8% |
| FCF margin | 15.8% | -11.9% | 1.8% | -1.0% | 4.5% |
| Return on assets | -1.3% | -4.5% | -7.8% | -9.0% | -18.3% |
| Return on equity | -9.8% | -25.1% | -34.5% | -51.0% | -159.6% |
| Debt / equity | 4.77× | 3.77× | 3.49× | 5.50× | 9.13× |
| Current ratio | 2.20 | 2.08 | 2.83 | 6.35 | 6.24 |
| Revenue growth | 36.4% | 53.3% | 47.0% | 22.2% | 48.3% |
Source: SEC EDGAR filings · CIK 0001360214 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.